Increased
endothelin-1 may be associated with elevation of blood pressure (BP) and promotion of vascular
hypertrophy, especially in
salt-sensitive
hypertension.
Mineralocorticoid hypertension has been associated with activation of the
endothelin system. We evaluated whether in
aldosterone-infused rats the selective
endothelin type A receptor-antagonist
BMS 182874 prevents BP elevation and vascular
hypertrophy. Rats were infused with
aldosterone (0.75 microg/h) subcutaneously via a mini-osmotic pump and were offered 1% NaCl in the
drinking water+/-
BMS 182874 (40 mg/kg in food) for 6 weeks. Systolic BP was monitored by the tail-cuff method, and vascular changes of mesenteric arteries were evaluated using a pressurized myograph.
Aldosterone-infusion significantly increased BP to 151+/-7 mm Hg compared with controls (108+/-4 mm Hg, P<0.01).
BMS 182874 normalized BP (117+/-4 mm Hg). Media cross-sectional area of aorta was significantly increased by
aldosterone infusion (P<0.05), and BMS treatment normalized it (P<0.001).
Aldosterone infusion increased media width and media-to-lumen ratio of mesenteric resistance arteries (17.6+/-0.4 microm and 7.5+/-0.4%) compared with controls (14.2+/-0.5 microm, P<0.01, and 5.9+/-0.1%, P<0.05).
BMS 182874 normalized media and media-to-lumen ratio (15.1+/-0.6 microm and 5.7+/-0.1%, both P<0.01). In conclusion, the
endothelin type A receptor antagonist attenuated BP elevation and prevented
vascular remodeling or
hypertrophy of aorta and mesenteric resistance arteries in
aldosterone-infused rats. These results suggest a role for
endothelin-1 in BP elevation and structural alterations of large and small vessels in
aldosterone and
salt-induced
hypertension.